| Literature DB >> 34986447 |
Han Wang1, Fang Yang1, Zhe-Wen Song1, Hao-Tian Shao1, Dong-Ying Bai1, Yan-Bo Ma1, Tao Kong1, Fan Yang2.
Abstract
This study aimed to determine whether the challenge from Escherichia coli (E. coli) lipopolysaccharide (LPS) affects the pharmacokinetics of danofloxacin in broilers. Twenty 1-day-old Arbor Acres (AA) broilers were equally and randomly divided into 2 groups. When the chickens were 23, 25, 27, and 29 days old, E. coli LPS (1 mL; 0.5 mg/kg body weight [BW]) and sterile saline (1 mL) were intraperitoneally injected into the two groups. After the last injection, danofloxacin was given to all chickens by gavage at the dose of 5 mg/kg BW. Then serum and plasma samples at each time point were collected through the wing vein. Danofloxacin concentrations in plasma were detected through the high-performance liquid chromatography (HPLC) method and subjected to noncompartmental analysis using Phoenix software. The levels of chicken interleukin-1β (IL-1β) and corticosterone (CORT) in serum were measured by the Enzyme-linked immunosorbent assay (ELISA) kit. In addition, after the collection of plasma or serum samples, 7 chickens (31 days of age) in each group were killed to calculate the organ indices. Compared with the control group, the challenge of LPS significantly decreased the parameters of AUC0-∞, Cmax, and t1/2λz and increased the parameters of Tmax and λz. Additionally, in the LPS group, the absorption time of danofloxacin was prolonged; however, the elimination was accelerated, which resulted in reduced internal exposure.Entities:
Keywords: Escherichia coli lipopolysaccharide; broiler; danofloxacin; pharmacokinetics
Mesh:
Substances:
Year: 2021 PMID: 34986447 PMCID: PMC8743212 DOI: 10.1016/j.psj.2021.101629
Source DB: PubMed Journal: Poult Sci ISSN: 0032-5791 Impact factor: 3.352
Comparison of mean organ indices (g/kg of body weight) (±SD) of broilers in the LPS and control group.
| Items | Control | LPS | |
|---|---|---|---|
| Heart | 5.85 ± 1.03 | 6.84 ± 0.63 | 0.051 |
| Liver | 29.21 ± 5.64 | 36.60 ± 2.93 | 0.010 |
| Spleen | 1.85 ± 0.59 | 2.96 ± 0.72 | 0.009 |
| Thymus | 2.90 ± 1.05 | 3.20 ± 1.01 | 0.593 |
| Bursa | 1.05 ± 0.21 | 1.30 ± 0.33 | 0.125 |
| Muscular stomach | 12.10 ± 2.18 | 13.31 ± 1.89 | 0.289 |
| Glandular stomach | 3.53 ± 0.60 | 4.54 ± 0.39 | 0.003 |
Control: sterile saline control group; LPS: E. coli LPS challenge group.
Abbreviations: LPS, lipopolysaccharide; SD, standard deviation.
There are significant differences between the two groups of parameters (P < 0.05).
Comparison of mean serum cytokine levels (±SD) of broilers between the LPS and control groups.
| Items | Control | LPS | |
|---|---|---|---|
| 2 h after the last injection of LPS | |||
| IL-1β (ng⋅L−1) | 160.85 ± 43.62 | 261.93 ± 66.79 | 0.022 |
| CORT (ng⋅mL−1) | 70.16 ± 39.95 | 149.91 ± 28.32 | 0.026 |
| 8 h after the last injection of LPS | |||
| IL-1β (ng⋅L−1) | 127.53 ± 53.48 | 163.83 ± 67.59 | 0.374 |
| CORT (ng⋅mL−1) | 95.33 ± 42.07 | 139.50 ± 54.33 | 0.298 |
| 24 h after the last injection of LPS | |||
| IL-1β (ng⋅L−1) | 66.65 ± 41.97 | 102.54 ± 44.26 | 0.225 |
| CORT (ng⋅mL−1) | 111.93 ± 55.11 | 132.59 ± 57.73 | 0.653 |
Control: sterile saline control group; LPS: E. coli LPS challenge group.
Abbreviations: CORT, corticosterone; IL-1β, interleukin-1β; LPS, lipopolysaccharide; SD, standard deviation.
There are significant differences between the two groups of parameters (P < 0.05).
Figure 1Mean ± SD plasma concentrations (μg/mL) of danofloxacin in the LPS and control groups after a single gavage of danofloxacin (5 mg/kg BW) in broilers. Control: sterile saline control group; LPS: E. coli LPS challenge group. Abbreviations: BW, body weight; LPS, lipopolysaccharide; SD, standard deviation.
Comparison of mean pharmacokinetic parameters (±SD) between the LPS and control groups after a single gavage of danofloxacin (5 mg/kg BW) in broilers (n = 10) (based on the results of noncompartmental analysis).
| Parameters | Unit | Control | LPS | |
|---|---|---|---|---|
| λz | 1/h | 0.07 ± 0.02 | 0.12 ± 0.04 | 0.001 |
| t1/2λz | h | 11.10 ± 3.12 | 6.21 ± 2.18 | 0.001 |
| Tmax | h | 2.92 ± 1.54 | 4.99 ± 1.42 | 0.006 |
| Cmax | μg/mL | 0.53 ± 0.17 | 0.36 ± 0.09 | 0.015 |
| AUC0-Tmax | h•μg/mL | 0.92 ± 0.39 | 1.02 ± 0.45 | 0.597 |
| AUC0-24h | h•μg/mL | 5.36 ± 1.50 | 4.19 ± 1.05 | 0.058 |
| AUC0-∞ | h•μg/mL | 6.94 ± 2.43 | 4.71 ± 1.57 | 0.028 |
| Vz/F | mL/kg | 12.31 ± 4.20 | 9.82 ± 3.26 | 0.157 |
| Cl/F | mL/h/kg | 0.82 ± 0.31 | 1.13 ± 0.25 | 0.023 |
| AUMC0-∞ | h2•μg/mL | 109.11 ± 58.86 | 54.26 ± 34.34 | 0.002 |
| MRT | h | 14.84 ± 3.45 | 11.01 ± 2.56 | 0.011 |
Control: sterile saline control group; LPS: E. coli LPS challenge group.
Abbreviations: AUMC0-∞: area under the first moment curve from the time of dosing to infinity; AUC0-Tmax, area under the concentration versus time curve from 0 to Tmax; AUC0-24h, area under the concentration versus time curve from 0 to 24 h; AUC0-∞, area under the concentration versus time curve from the time of dosing to infinity; BW, body weight; λz, first-order rate constant associated with the terminal phase; Cmax, peak concentration; Cl/F, ratio of body clearance rate and bioavailability; MRT, mean residence time extrapolated to infinity; LPS, lipopolysaccharide; t1/2λz, terminal half-life; Tmax, time to reach peak concentration; SD, standard deviation; Vz/F, ratio of apparent distribution volume and bioavailability based on terminal phase.
There are significant differences between the two groups of parameters (P < 0.05).